摘要
目的观察重组人干扰素α-1b联合思密达治疗手足口病的临床疗效。方法将85例手足口病患儿随机分为对照组43例和治疗组42例,对照组肌注重组人干扰素α-1b行常规治疗,治疗组在常规治疗基础上联用思密达涂口腔治疗。观察对比两组疗效。结果治疗组住院时间、退热时间、开始进食时间及口腔溃疡消失时间均短于对照组(P<0.05),2组手足皮疹消退时间比较差异无统计学意义(P>0.05),两组均未发现不良反应。结论重组人干扰素α-1b联合思密达治疗手足口病可显著提高临床有效率,缩短病程,且无明显毒副作用。
Objective To observe the therapeutic effect of interferon α-1b combined with smecta in the treatment of hand-foot-mouth disease in children.Methods There 85 children with hand-foot-mouth disease who orally received interferon α-1b for im were randomly divided into 2 groups,The control group（42 cases）treatment concentional therapy and the observation group（43 cases）took smecta orally at the same time in addition to conventional therapy.The therapeutic effects of the 2 groups were observed.Results The hospitalization duration,defervescence time,the time of intake food and the disappearing time of mouth ulcers in the observation group were shorter than those of the control group（P0.01）.But there was no significant difference between the two groups of the disappearing time of hand-foot rash（P0.05）.No obvious toxic and adverse effects occurred.Conclusion The combination of interferon α-1b and smecta in the treatment of children with hand-foot-mouth disease can enhance the clinical efficacy,shorten the course of disease with no obvious toxic and side effects.
出处
《中国热带医学》
CAS
2011年第9期1133-1133,1137,共2页
China Tropical Medicine
关键词
手足口病
干扰素
思密达
Hand-foot-mouth disease
Interferon
Smecta
